Aspen Neuroscience, Inc.
Aspen Neuroscience filed Amendment No. 2 to its S-1 for an IPO of 9,375,000 shares at an expected price range of $15.00 to $17.00 per share, targeting a Nasdaq listing under "ASPE." The clinical-stage biotech is developing autologous iPSC-derived cell therapies for neurodegenerative diseases, led by sasineprocel for Parkinson's disease, currently in a Phase 1/2a trial with 15 patients dosed.
- Offering 9,375,000 shares at $15.00–$17.00 per share, with a 1,406,250-share underwriter option.
- Lead candidate sasineprocel is in a Phase 1/2a ASPIRO trial for Parkinson's disease; 15 patients dosed as of August 18, 2026.
- Sasineprocel has RMAT and Fast Track designations from the FDA for Parkinson's disease.
- Phase 3 biopsy collection expected by end of 2026; Phase 3 dosing anticipated in H2 2027.
- Autologous iPSC platform eliminates need for immunosuppression; no graft rejection observed in trial to date.
Price data unavailable.
First pure-play autologous iPSC cell therapy for Parkinson's to file for IPO — if successful, sasineprocel would be the first disease-modifying PD treatment without immunosuppression.
Aspen joins a wave of biotech IPOs targeting neurodegenerative disease with cell-replacement therapies. Competitors include allogeneic approaches (BlueRock/Bayer, Novo Nordisk) that require immunosuppression — Aspen's autologous model is a key differentiator if scalable.
Open-label Phase 1/2a trial lacks placebo control; results may not predict outcomes in controlled registrational studies. Autologous manufacturing at scale is unproven — each dose is patient-specific, creating complex logistics and cost challenges.